Doctors are not safe with some patients.

Published Date: 16 Feb 2023

Many physicians have encountered one or more serious or potentially dangerous patients over the years, and according to Medscape research, patient trust has declined.

Read Full News

Latest News

This Test Could Predict Incontinence Risk After HoLEP

Men with a shorter membranous urethra appear more likely to experience urinary incontinence after laser enucleation for benign prostatic hyperplasia, a new study shows.

Smartphone App Helps Delay Ejaculation

The app improves sexual control and doubles ejaculation latency time in a randomized trial.

US FDA Approves Lantheus' New Prostate Cancer Imaging Formulation

The U.S. Food and Drug Administration on Friday approved a new formulation of Lantheus Holdings' prostate ⁠cancer imaging agent, aimed at improving scanning access through...

Will a Smart Toilet Turn the Home Into a Diagnostic Center?

Smart toilets show promise for passive monitoring of stool and urine to detect potential health issues, but challenges remain.

Bayer Sues Johnson & Johnson Over Claim That Prostate Cancer Drug Cuts Risk Of Death

Bayer sued Johnson & Johnson on Monday, accusing the drugmaker of falsely advertising that its rival multibillion-dollar drug cuts the ⁠risk of death from prostate...

Doc Murdered 8 Patients? RFK Jr. Will 'Cost Lives'; $412M in Penile Injection Case

Health news and commentary gathered by MedPage Today staff

Todays Updates

ctDNA-Guided Adjuvant Therapy Cuts Bladder Cancer Costs

Researchers evaluate whether postoperative ctDNA-guided adjuvant atezolizumab after radical cystectomy is cost-effective compared with standard care in patients with muscle-invasive bladder cancer.

PSA Often Unchanged With Enzalutamide Progression

A stable PSA level does not rule out progression in men taking enzalutamide for advanced prostate cancer.

Todays Updates

ctDNA-Guided Adjuvant Therapy Cuts Bladder Cancer Costs

Researchers evaluate whether postoperative ctDNA-guided adjuvant atezolizumab after radical cystectomy is cost-effective compared with standard care in patients with muscle-invasive bladder cancer.

PSA Often Unchanged With Enzalutamide Progression

A stable PSA level does not rule out progression in men taking enzalutamide for advanced prostate cancer.

Latest News

Men with a shorter membranous urethra appear more likely to experience urinary incontinence after laser enucleation for benign prostatic hyperplasia, a new study shows.

The app improves sexual control and doubles ejaculation latency time in a randomized trial.

The U.S. Food and Drug Administration on Friday approved a new formulation of Lantheus Holdings' prostate ⁠cancer imaging agent, aimed at improving scanning access through...

Smart toilets show promise for passive monitoring of stool and urine to detect potential health issues, but challenges remain.

Bayer sued Johnson & Johnson on Monday, accusing the drugmaker of falsely advertising that its rival multibillion-dollar drug cuts the ⁠risk of death from prostate...

Health news and commentary gathered by MedPage Today staff

News All Time

King Charles III's Operation; COVID-19 Timeline Under Question; FDA Approvals Reach Record High.

The staff of MedPage Today has compiled health news and commentary from around the web.

Noninvasive Treatment Effective in Bladder Cancer That Is Not Muscle-Invasive.

An investigational intrusive solution produced a 79% complete response rate.

For Prostate Cancer at Intermediate Risk, SBRT Is Not Less Effective Than Conventional RT.

Similar results are obtained from treatment lasting one to two weeks as compared to therapy lasting up to seven and a half weeks.

Even in those with HIV, a single dose of antibiotics was able to cure early syphilis.

In a randomized trial, one dosage showed no worse results than a triple-dose regimen.

Should Patients With Advanced Prostate Cancer Get Off the Active Surveillance Train?

Clearly defined rules are needed.

The new first-line standard for advanced bladder cancer was produced by a landmark trial.

When compared to chemotherapy, enfortumab vedotin-pembrolizumab doubles OS and PFS.

An RCT Supports HIF-2a Inhibition in Advanced RCC.

Belzutifan outperforms everolimus in the event of immunotherapy-TKI failure.

AR-Pathway Inhibitor Switch for mCRPC is Superseded by Radionuclide Therapy.

With 177Lu-PSMA-617, the time to radiographic progression was doubled.

Cabazitaxel Lower-Dose Schedule Is Viable for Elderly Patients With mCRPC.

Neutropenia of grade three or above, with a twelve-fold reduction in neutropenic consequences.

Removing Cancer Survivors From Oncologic Treatment.

A new approach to care is required.

In severe cases of renal cell carcinoma, tyrosine kinase inhibitor activity is present.

Reactions to the "special medication" zanzalintinib in patients exposed and not exposed to cabozantinib.

Finding New Routes to Improve Renal Cell Carcinoma Outcomes.

It is necessary to intervene at several stages of the cancer immunity cycle in order to build on recent successes.

CAR T-Cell Therapy for Renal Cell Carcinoma: "We're Not There Yet".

Possibility of standard of care following current therapies, but significant barriers still need to be overcome.

Dietary inflammation is associated with the development of urologic cancers.

In health research, the relationship between dietary habits and cancer risks is still a major focus. The has been the subject of a recent meta-analysis.

In infants, laparoscopic robotic pyeloplasty is safe and has a success rate comparable to open surgery.

The results of minimally invasive pyeloplasty (MIP) for the primary cause, ureteropelvic junction obstruction (UPJO), were examined in a recent study.

Medical Bulletin November 30, 2023.

The top medical stories of the day are as follows: ADHD increases the risk of car crashes in older adults. ADHD is a neurodevelopmental disorder that is chronic and has symptoms.

Recommended News For You

The origin of BPH and prostate cancer in different prostate zones and the impact on the incidence of prostate cancer

I Understand Why Defense Secretary Austin Kept His Prostate Cancer Quiet.

Quads, Frailty, and the Future: Evolving Frontline Strategies in Multiple Myeloma

Minimally invasive prostate cancer treatment shows success in first patient

Big PFS Increase in Advanced Neuroendocrine Tumors With Combination Therapy

CAR-T Warning for Secondary Malignancies: Warranted or Not?

Losing a reward can affect your motivation and performance.

Recommended Articles For You

Cutting-Edge Cancer Treatments: Innovations and Outcomes in Non-Hodgkin Lymphoma 

Studying Lactic Acid in Pediatric Tumor Microenvironments: Experimental Approaches Explored 

Transplant Oncology and Anti-Cancer Immunosuppressants: The Evolution of a Paradigm in Cancer Care 

Strategic Deals and FDA Approvals Transforming U.S. Oncology Drug Development 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Have the Harms of Lung Cancer Screening Been Exaggerated?

2.

Radioactive ion beams successfully treat animal tumors in study

3.

In R/R Follicular Lymphoma, Tisa-Cel Produces Long-Lasting Responses.

4.

Bladder cancer link to explosive ordnance exposure among Army veteran bomb disposal officers

5.

EU Adds CAR-T Warning; New Blincyto Indication; Good News in Pancreatic Cancer

1.

Chronic Cancer Survivorship: Managing Long-Term Outcomes with Precision Care

2.

Revolutionizing Lung Transplantation: The Promise of Donor-Specific Blood Transfusion

3.

Ultimate Guide to Oncology Services in the USA

4.

Unlocking the Mysteries of Synovial Sarcoma: A New Hope for Treatment

5.

Exploring the Effects of Radiation Therapy on Cystitis: A Journey to Better Health

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part IV

2.

The Comprehensive Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2.

3.

Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer

4.

From Relapse to Remission: Mapping the Treatment Journey in Adult R/R-Cell ALL - Part 2

5.

Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part V

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot